Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2000

View Archived Issues

Medeva's Hepagene study shows promising results as treatment of chronic HBV

Periodontix raises funding for further development of HistaWash

Pharmacia & Upjohn and Geron extend telomerase collaboration

Therapeutic protein discovery partnership formed by Bayer and Incyte

Afferon steps up development of RTX for treatment of urge incontinence

Arena granted SBIR award for atypical antipsychotics

Neurocrine Biosciences updates clinical progress with IL-4 fusion toxin

SmithKline Beecham signs CpG DNA immune stimulant agreement

FDA approves two-dose regimen of Merck & Co.'s Recombivax HB for adolescent use

Positive results for memantine in phase IIb trial for treatment of neuropathy

Human Genome Sciences initiates phase II clinical trial of repifermin for mucositis

Synthesis, use of series of PDE4 inhibitors reported by Merck

Compounds active at human 5-HT1A receptors designed at AHP

Selective inhibitors of alpha4 integrin binding for inflammatory, immune disorders

Pfizer patents new series of COX-2 inhibitors with sulfonybenzene structure

Melanocortin receptor agonists and their use disclosed by Merck

Schering's new agents for eating disorders and diabetes presented in international patent

Novel amidino derivatives and their use as NOS inhibitors reported by Searle

Wide series of cell adhesion inhibitors in the Merck pipeline

German colorectal cancer patients have new treatment option: Sanofi-Synthelabo's Eloxatin

Enhancement of both upper and lower GI motility associated with selective 5-HT4 agonist

Ramipril and aminoguanidine both prevent albuminuria and normalize PKC in diabetic rats

Lipitor recommended for approval in Japan

RPR-120844: pharmacodynamic and antithrombotic profile of a new factor Xa inhibitor

Barr and DuPont to establish collaborative agreement

NAALADase inhibition as an effective and safe therapeutic strategy for stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...